

Frontotemporal Dementia Pipeline Therapeutics, Clinical Trials Assessment, Emerging Drugs and Companies | DelveInsight

Frontotemporal Dementia Pipeline

LAS VEGAS, NV, UNITED STATES, January 20, 2025 /EINPresswire.com/ -- DelveInsight's, "Frontotemporal Dementia Pipeline Insight" report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Frontotemporal Dementia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.



Discover the latest drugs and treatment options in the Frontotemporal Dementia Pipeline. Dive into DelveInsight's comprehensive report today! @ [Frontotemporal Dementia Pipeline Outlook](#)

Key Takeaways from the Frontotemporal Dementia Pipeline Report

- In December 2024:- Prevail Therapeutics:- Study J4B-MC-OKAA is a Phase 1/2, multi-center, open-label ascending dose, first-in-human study that will evaluate the safety and effect of intracisternal LY3884963 administration on progranulin protein (PGRN) levels in patients with frontotemporal dementia with progranulin mutations (FTD-GRN). Two escalating dose (low dose and medium dose) cohorts are planned, as well as one bridging cohort which will allocate patients to receive either low or medium dose. The duration of the study is 5 years.
- DelveInsight's Frontotemporal Dementia pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Frontotemporal Dementia treatment.
- The leading Frontotemporal Dementia Companies such as Transposon Therapeutics, Alector, Vesper Bio, AviadoBio, Passage Bio, Eli Lilly and Company, Coya Therapeutics, Neurimmune

Therapeutics, Asceneuron SA., and others

- Promising Frontotemporal Dementia Therapies such as LY3884963, DNL593, AL001, PBFT02, Olipudase alfa, and others

Stay ahead with the most recent pipeline outlook for Frontotemporal Dementia. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ [Frontotemporal Dementia Treatment Drugs](#)

Frontotemporal Dementia Emerging Drugs Profile

- AL001: Alector

AL001 is a recombinant human anti-human sortilin (SORT1) monoclonal IgG1 developed by Alector in partnership with GSK. It aims to increase the level of progranulin in humans by inhibiting a progranulin degradation mechanism. The antibody received orphan drug designation, fast track designation, and breakthrough designation from the US FDA for the treatment of frontotemporal dementia. Alector Inc. is currently investigating AL001 in Phase III clinical trials for FTD with a C9orf72 mutation and granulin mutation.

- TPN-101: Transposon Therapeutics

TPN-101 specifically inhibits the LINE-1 reverse transcriptase that promotes LINE-1 replication. LINE-1 elements are a class of retrotransposable elements that in humans are uniquely capable of replicating and moving to new locations within the genome. When this process becomes dysregulated, LINE-1 reverse transcriptase drives overproduction of LINE-1 DNA, triggering innate immune responses that contribute to neurodegenerative, autoimmune and aging-related disease pathology. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Frontotemporal Dementia.

- AVB-101: AviadoBio

AVB-101 is a potential one-time therapy designed to stop disease progression by delivering a functional copy of the GRN gene to restore appropriate progranulin levels to affected areas of the brain. The drug is delivered using a minimally invasive, stereotactic neurosurgical procedure directly to the part of the brain called the thalamus. The thalamus has extensive connections to other parts of the brain, including the frontal and temporal lobes, which play a critical role in FTD and the symptoms that impact patients and their families.

- VES001: Vesper Bio

VES001 is the first oral, brain penetrant, small molecule sortilin inhibitor designed as a potentially disease-modifying treatment for the neuro-cognitive disorder fronto-temporal dementia (FTD (GRN)). Data returned from this study (NCT06226064) demonstrate the safety and tolerability of VES001 across the full range of doses tested and show it has excellent pharmacokinetics and distribution to relevant parts of the brain.

Explore groundbreaking therapies and clinical trials in the Frontotemporal Dementia Pipeline.

Access DelveInsight's detailed report now! @ [New Frontotemporal Dementia Drugs](#)

Frontotemporal Dementia Companies

Transposon Therapeutics, Alector, Vesper Bio, AviadoBio, Passage Bio, Eli Lilly and Company, Coya Therapeutics, Neurimmune Therapeutics, Asceneuron SA., and others.

Frontotemporal Dementia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal

Frontotemporal Dementia Products have been categorized under various Molecule types such as

- Oligonucleotide
- Peptide
- Small molecule

Unveil the future of Frontotemporal Dementia Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Frontotemporal Dementia Market Drivers and Barriers- https://www.delveinsight.com/sample-request/frontotemporal-dementia-pipeline-insight?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Frontotemporal Dementia Pipeline Report

- Coverage- Global
- Frontotemporal Dementia Companies- Transposon Therapeutics, Alector, Vesper Bio, AviadoBio, Passage Bio, Eli Lilly and Company, Coya Therapeutics, Neurimmune Therapeutics, Asceneuron SA., and others.
- Frontotemporal Dementia Therapies- LY3884963, DNL593, AL001, PBFT02. Olipudase alfa, and others
- Frontotemporal Dementia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Frontotemporal Dementia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Frontotemporal Dementia Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Frontotemporal Dementia Companies, Key Products and Unmet Needs- https://www.delveinsight.com/sample-request/frontotemporal-dementia-pipeline-insight?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr

Table of Content

1. Introduction
2. Executive Summary
3. Frontotemporal Dementia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Frontotemporal Dementia- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Latozinemab: Alector
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. Drug Name: Company Name
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I/II)
14. PR 006 : Prevail Therapeutics
15. Drug profiles in the detailed report.....
16. Preclinical and Discovery Stage Products
17. EXO-050: Coya Therapeutics
18. Drug profiles in the detailed report.....
19. Inactive Products
20. Frontotemporal Dementia Key Companies
21. Frontotemporal Dementia Key Products
22. Frontotemporal Dementia- Unmet Needs
23. Frontotemporal Dementia- Market Drivers and Barriers
24. Frontotemporal Dementia- Future Perspectives and Conclusion
25. Frontotemporal Dementia Analyst Views
26. Frontotemporal Dementia Key Companies
27. Appendix

List of Top Selling Market Research Reports in 2025

Varicose Vein Treatment Devices Market - <https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market>

Vascular Access Devices Market - <https://www.delveinsight.com/report-store/vascular-access-device-market>

Indwelling Catheters Market - <https://www.delveinsight.com/report-store/indwelling-catheters-market>

Healthcare Competitive Benchmarking - <https://www.delveinsight.com/consulting/competitive->

[benchmarking-services](#)

Lymphoedema Market - <https://www.delveinsight.com/report-store/lymphoedema-market>

Pacemakers Market - <https://www.delveinsight.com/report-store/pacemakers-market>

Myeloproliferative Neoplasms Market - <https://www.delveinsight.com/report-store/myeloproliferative-neoplasms-market>

Surgical Mask & Respirator Market - <https://www.delveinsight.com/report-store/surgical-mask-respirator-market>

Nk Cell Therapy Market - <https://www.delveinsight.com/report-store/nk-cell-therapy-market>

Novel Drug Delivery Devices Market - <https://www.delveinsight.com/report-store/novel-drug-delivery-devices>

Testicular Neoplasm Market - <https://www.delveinsight.com/report-store/testicular-cancer-pipeline-insight>

Phototherapies For Psoriasis Market - <https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market>

Skin Neoplasm Market - <https://www.delveinsight.com/report-store/nonmelanoma-skin-cancer-market>

Microscopy Device Market - <https://www.delveinsight.com/report-store/microscopy-device-market>

Bone Growth Stimulator Market - <https://www.delveinsight.com/report-store/bone-growth-stimulators-market>

Urea Cycle Disorders Market - <https://www.delveinsight.com/report-store/urea-cycle-disorders-market>

Antibody Drug Conjugate Market - <https://www.delveinsight.com/report-store/antibody-drug-conjugate-market>

Penile Cancer Market - <https://www.delveinsight.com/report-store/penile-implants-market>

Total Knee Arthroplasty Market - <https://www.delveinsight.com/report-store/total-knee-arthroplasty-market>

Cardiac Implantable Electronic Devices Market - <https://www.delveinsight.com/report-store/cardiac-implantable-electronic-devices-cieds-market>

Dyspepsia Market - <https://www.delveinsight.com/report-store/functional-dyspepsia-epidemiology-forecast-insight>

Lactose Intolerance Market - <https://www.delveinsight.com/report-store/lactose-intolerance-market>

Medical Marijuana Market - <https://www.delveinsight.com/report-store/medical-marijuana-market-insight>

Asperger Syndrome Market - <https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market>

Catheter Stabilization Devices Market - <https://www.delveinsight.com/report-store/catheter-stabilization-securement-device-market>

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides

clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Yash Bhardwaj
DelveInsight
+91 96502 13330
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/778598906>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.